Cargando…
Treatment of hepatitis C virus infection in the future
Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally resu...
Autores principales: | Kanda, Tatsuo, Yokosuka, Osamu, Omata, Masao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637513/ https://www.ncbi.nlm.nih.gov/pubmed/23577631 http://dx.doi.org/10.1186/2001-1326-2-9 |
Ejemplares similares
-
Hepatitis C Virus and Hepatocellular Carcinoma
por: Kanda, Tatsuo, et al.
Publicado: (2013) -
Faldaprevir for the Treatment of Hepatitis C
por: Kanda, Tatsuo, et al.
Publicado: (2015) -
Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014) -
New treatments for genotype 1 chronic hepatitis C – focus on simeprevir
por: Kanda, Tatsuo, et al.
Publicado: (2014) -
Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
por: Miyamura, Tatsuo, et al.
Publicado: (2011)